Journal Mobile Options
Table of Contents
Vol. 18, No. 1, 2000
Issue release date: 2000
Dig Dis 2000;18:20–26

Empirical Trials in Treatment of Gastroesophageal Reflux Disease

Fass R.
Department of Medicine, Section of Gastroenterology, Southern Arizona V.A. Halth Care System and University of Arizona Health Sciences Center, Tucson, Ariz., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The assortment of diagnostic tests that are currently available for detecting gastroesophageal reflux disease (GERD) are invasive, costly and not readily available to community-based physicians. In contrast, a short course of high-dose proton pump inhibitor (PPI) as an empirical trial is an attractive alternative. This simple diagnostic test has been demonstrated to be accurate and cost-effective in patients with symptoms suggestive of GERD and those with noncardiac chest pain. Early studies in patients with extraesophageal manifestations of GERD have yielded promising results. Cost assessment of the PPI empirical trial revealed significant cost savings, mainly due to a marked decrease in utilization of invasive diagnostic tests. Thus the PPI empirical trial should be considered as the initial diagnostic step in patients with the disease spectrum of GERD.

Copyright © 2000 S. Karger AG, Basel

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. The Gallup Organization Inc. A Gallup survey of heartburn across America, 1988.
  2. Nebel O, Fornes M, Castell D: Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis 1976;21:953–956.
  3. Deschner WK, Benjamin SB: Extraesophageal manifestations of gastroesophageal reflux disease. Am J Gastroenterol 1989;84:1–5.
  4. Locke GR, Talley N, Fett S, Zinsmeister A: Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmstead County, Minnesota. Gastroenterology 1997;112:1448–1456.
  5. Johansson KE, Ask P, Boeryd B, et al: Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:837–847.
  6. Richter JE, et al: Functional esophageal disorders; in Drossman D, et al (eds): The Functional Gastrointestinal Disorders. Boston, Little, Brown, 1994, pp 25–70.
  7. Rodriquez SL, Robinson M, Earnest D, Maton P, et al: Esophageal hypersensitivity: A major cause of heartburn? Gastroenterology 1997;112:A270.
  8. Ott DJ, Chen YM, Gelfand DW, Munitz HA, Wu WC: Analysis of a multiphasic radiographic examination for detecting reflux esophagitis. Gastrointest Radiol 1986;11:1–6.

    External Resources

  9. Dent J, Brun J, Fendrick A, et al: An evidence-based appraisal of reflux disease management – The Genval workshop report. Gut 1999;44(suppl 2):1–16.
  10. Wu WC: Ancillary tests in the diagnosis of gastroesophageal reflux disease. Gastroenterol Clin North Am 1990;19:671–681.
  11. Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RO, Reece A: Peristaltic dysfunction in peptic esophagitis. Gastroenterology 1986;91:897–904.
  12. Cohen S, Harris LD: Does hiatal hernia affect competence of the gastroesophageal sphincter? N Engl J Med 1971;284:1053–1056.

    External Resources

  13. Dent J, Dodds WJ, Friedman RH, Sekiguchi T, Hogan WJ, Arndorfer RC, Petrie DJ: Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980;65:256–267.
  14. Euler AR, Byrne WJ: Twenty-four-hour esophageal intraluminal pH probe testing: A comparative analysis. Gastroenterology 1981;80:957–961.

    External Resources

  15. Richter JE, Castell DO: Gastroesophageal reflux: Pathogenesis, diagnosis, therapy. Ann Intern Med 1982;97:93–103.
  16. Behar J, Biancani P, Sheahan DG: Evaluation of esophageal tests in the diagnosis of reflux esophagitis. Gastroenterology 1976;71:9–15.

    External Resources

  17. Fass R, Fennerty MB, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE: The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998;115:42–49.
  18. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HPM, Jansen EH, Tuynman HARE, et al: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997;92:1997–2000.
  19. Fass R, Ofman JJ, Fennerty MB: High-dose omeprazole in patients with noncardiac chest pain. Gastroenterology 1999;116:226–227.
  20. Schindlebeck NE, Klauser AG, Voderholzer WA, Muller-Lissner SA: Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995;155:1808–1812.
  21. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L: One week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998;33:15–20.
  22. Fass R, Fennerty MB, Yalam JM, Camargo L, Garewal H, Grade A, Sampliner RE: Evaluation of the omeprazole test in patients with typical symptoms of gastroesophageal reflux disease. Gastroenterology 1999;112:A114.
  23. Young MF, Sanowski RA, Talbert GA, Harrison ME, Walker BE: Omeprazole administration as a test for gastroesophageal reflux (abstract). Gastroenterology 1992;102:192.
  24. Squillace SJ, Young MF, Sanowski RA: Single dose omeprazole as a test for noncardiac chest pain. Gastroenterology 1993;104:A197.
  25. Metz D, Childs ML, Ruiz C, Weinstein GS: Pilot study of the oral omeprazole test for reflux laryngitis. Otolaryngol Head Neck Surg 1997;116:41–46.
  26. Ours TM, Kavuru MS, Schiz RJ, Richter JE: Prospective, double-blind study comparing omeprazole 40 mg bid vs. placebo in patients with chronic cough and GE reflux. Am J Gastroenterol 1998;93:1621A.
  27. Jaspersen D, Diehl KL, Geyer P, Martens E: Omeprazole test for gastroesophageal reflux-related chronic persistent cough. Gastroenterology 1999;116:G0861.
  28. Fass R, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE, Fennerty MB: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999;159:2161–2168.
  29. Lawrence L: National Center for Health Statistics. Detailed diagnoses and procedures for patients discharged from short-stay hospitals, United States, 1984. Hyattsville, Md., US Department of Health and Human Services, Public Health Services, National Center for Health Statistics, 1986. Vital and Health Statistics, Series 13;86.
  30. Hewson EG, Sinclair JW, Dalton CB, Richter JE: Twenty-four hour esophageal pH monitoring. The most useful test for evaluating noncardiac chest pain. Am J Med 1991;90:576–583.
  31. Janssen J, Vantrappen G, Ghillibert G: 24-hour recording of esophageal pressure and pH in patients with noncardiac chest pain. Gastroenterology 1986;90:1978–1984.
  32. DeCaestecker JS, Blackwell JN, Brown J, Heading RC: The oesophagus as a cause of recurrent chest pain: Which patients should be investigated and which tests should be used? Lancet 1985;ii:1143–1146.
  33. Singh SA, Richter JE, Hewson EG, Sinclair JW, Hackshaw BT: The contribution of gastroesophageal reflux to chest pain in patients with coronary artery disease. Ann Intern Med 1992;117:824–830.
  34. Stahl WG, Beton RR, Johnson CS, Brown CL, Waring JP: High-dose ranitidine in the treatment of patients with non-cardiac chest pain and evidence of gastroesophageal reflux disease. Gastroenterology 1992;102:A168.
  35. Achem SR, Kolts BE, MacMath T, Richter JE, Mohr D, Burton L, Castell DO: Effects of omeprazole vs. placebo in treatment of noncardiac chet pain and gastroesophageal reflux. Dig Dis Sci 1997;42:2138–2145.
  36. Fass R, Fennerty MB, Johnson C, Camargo L, Sampliner RE: Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patient with noncardiac chest pain due to gastroesophageal reflux disease. J Clin Gastroenterol 1999;28:36–39.
  37. Castell DO, Katz PO: The acid suppression test for unexplained chest pain (editorial). Gastroenterology 1998;115:222–224.
  38. Sontag SJ, O’Connell S, Khandelwal S, et al: Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990;99:613–620.
  39. Fraser AG: Gastro-esophageal reflux and laryngeal symptoms. Aliment Pharmacol Ther 1994;8:265–272.
  40. Olson NR: Laryngopharyngeal manifestations of gastroesophageal reflux disease. Otolaryngeal Clin North Am 1991;24:1201–1213.
  41. Ott DJ, Ledbetter MS, Koufman JA, Chen MYM: Globus pharyngeus: Radiographic evaluation and 24-hour pH monitoring of the pharynx and esophagus in 22 patients. Radiology 1994;191:95–97.
  42. McNally PR, Mayodonovitch CL, Prosek RA, Collette RP, Wong RK: Evaluation of gastroesophageal reflux as a cause of idiopathic hoarseness. Dig Dis Sci 1989;34:1900–1904.
  43. Kamel PL, Hanson D, Hahrilas PJ: Omeprazole for the treatment of posterior laryngitis. Am J Med 1994;96:321–326.
  44. Field SK, Sutherland LR: Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux? Chest 1998;114:275–283.
  45. Wo JM, Grist WJ, Gussack G, Delgaudio JM, Waring JP: Empiric trial of high-dose omeprazole in patients with posterior laryngitis: A prospective study. Am J Gastroenterol 1997;92:2160–2165.
  46. Bate CM, Riley SA, Chapman RWG, Durnin AT, Taylor MD: Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:59–66.
  47. Ofman J, Gralnek I, Udani J, Fass R: The cost-effectiveness of the omeprazole test in noncardiac chest pain. Gastroenterology 1998;114:A31(G0127).
  48. Ofman JJ, Gralnek IM, Udani J, Fennerty MB, Fass R: The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999;107:219–227.
  49. Fass R, Ofman JJ: Omeprazole test and 24-hour esophageal pH monitoring in diagnosing GERD. Gastroenterology 1999;116:1012–1013.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50